Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Pharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBIO alertsJulie Miller Everett has spoken on 1 investor event across 1 company, most recently for BridgeBio Pharma, Inc. on June 9, 2026. BridgeBio Pharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Pharma, Inc. includes Neil Kumar (CEO and Board Member), Charles Homcy (Chairman and Board Member), Brian Stephenson (CFO) and 7 others.
“So I think for us, we anticipate it being a little bit more even moving forward between U.S. and ex-US. And part of that, if you take a look at the U.S. market specifically, We know that there's about 3,400 patients that are eligible, pediatric patients eligible with open epithesis for therapy.”
Transcript header (unverified)
Biotechnology · Healthcare
